"Having dedicated my career to improving the clinical care of men and women diagnosed with cancer through molecular insight enabled by genomics, I am thrilled to contribute to Genomic Health's mission to limit overtreatment while at the same time expanding the number of individuals who can potentially benefit. With over 600,000 patients having benefitted from our tests and our proven "team science" approach, I am confident that this is just the beginning."
After 20 years as a physician scientist at leading Institutes throughout the country, Phil Febbo, joined Genomic Health as Chief Medical Officer in 2013. Immediately prior to Genomic Health, Phil served as Professor of Medicine and Urology at the University of California, San Francisco where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology. While at UCSF, Phil was the Co-Leader of the Prostate Cancer Program at the UCSF Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology. Phil holds a Bachelor of Arts degree in Biology from Dartmouth College, received his M.D. degree at the University of California, San Francisco and completed his internal medicine residency at the Brigham and Women' s Hospital in Boston, Massachusetts. After his fellowship in medical oncology at the Dana Farber Cancer Institute, he was an Attending Physician in the Genitourinary Oncology Center at the Dana Farber Cancer Institute, Instructor at Harvard Medical School, and a post-doctoral fellow in Dr. Todd Golub's laboratory at the Dana Farber Cancer Institute as well as the Whitehead Institute Center for Genomic Research of MIT (now the Broad Institute). In 2004, Phil moved to Duke University Medical Center’s Institute of Genome Sciences and Policy. In 2010, he returned to UCSF. Phil’s laboratory was funded by the National Institutes of Health, Department of Defense, Damon Runyon Cancer Research Foundation, and the Prostate Cancer Foundation. He has been a member of the American Society for Clinical Investigation since 2009.